Aravive Beheer
Beheer criteriumcontroles 0/4
Momenteel beschikken wij niet over voldoende informatie over de CEO.
Belangrijke informatie
Algemeen directeur
n/a
Totale compensatie
Percentage CEO-salaris | n/a |
Dienstverband CEO | no data |
Eigendom CEO | n/a |
Management gemiddelde ambtstermijn | geen gegevens |
Gemiddelde ambtstermijn bestuur | geen gegevens |
Recente managementupdates
Recent updates
Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely
Apr 26Here's Why Aravive (NASDAQ:ARAV) Must Use Its Cash Wisely
Sep 03Aravive Q2 GAAP EPS misses, revenue beats
Aug 11Aravive appoints Robert Geller as CMO
Jul 05We Think Aravive (NASDAQ:ARAV) Needs To Drive Business Growth Carefully
May 15Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth
Nov 06Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth
Jun 25Aravive EPS beats by $0.01, misses on revenue
May 06Aravive shares rise after dosing first patient in late-stage ovarian cancer study
Apr 27Did Business Growth Power Aravive's (NASDAQ:ARAV) Share Price Gain of 121%?
Mar 18Companies Like Aravive (NASDAQ:ARAV) Are In A Position To Invest In Growth
Feb 09Aravive: Pipeline-In-A-Pill In Oncology
Dec 28Aravive (ARAV) Investor Presentation - Slideshow
Dec 04Aravive late-stage study of AVB-500 in platinum-resistant ovarian cancer part of FDA's innovative trial design initiative
Nov 19Aravive, 3D Medicine inks licensing pact for AVB-500 for Greater China
Nov 10CEO
Aravive heeft geen CEO, of we hebben geen gegevens over hen.